All In Biotech

Drug Trial Radar · NCT07486024

Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)

Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France - FAST-MDR

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Sep 11, 2026

Primary completion

Aug 2030

Study completion Feb 2032

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Viatris Inc.
First posted
Mar 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The FAST-MDR trial is an externally-controlled, multicentre trial with one prospective arm, evaluating the non-inferiority of the effectiveness of BPaLM in the interventional arm versus the effectiveness of the long, conventional regimen in a French historical cohort of MDR-TB patients (2006-2022). In light of recent WHO recommendations suggesting using BPaLM as a first choice for routine MDR-TB treatment and of the expected benefits of BPaLM over the standard treatment, there will be no internal comparator arm in the study.

Conditions

  • MDR-TB
  • Tuberculosis Multi Drug Resistant Active
  • Antibiotic Resistance
  • Mycobacterium Tuberculosis

Interventions

  • Bedaquiline Oral TabletDrug

    Bedaquiline will be given as 400 mg once daily for 2 weeks and then 200 mg thrice weekly for the remaining 22 weeks

  • Bedaquiline Oral TabletDrug

    Bedaquiline will be given as 200 mg once daily for 8 weeks and then 100 mg daily for the remaining 16 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effectiveness of BPaLM compared to conventional MDR-TB regimensTime frame: Day 0 to Month 18

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Amiens

    Amiens, France · Recruiting

  • CHU Bichat - Claude-Bernard

    Paris, France · Recruiting

  • Pitié-Salpêtrière Hospital - infectious and tropical diseases

    Paris, France · Not yet recruiting

  • CHU Rennes

    Rennes, France · Recruiting

  • CHU Toulouse - Hôpital Purpan

    Toulouse, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.